Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Dec;104(6):1074-1081.
doi: 10.1002/cpt.1212. Epub 2018 Sep 24.

Current State of Microbicide Development


Current State of Microbicide Development

Yannick L Traore et al. Clin Pharmacol Ther. .


Efforts in developing an effective vaccine for human immunodeficiency virus (HIV) has been challenging as HIV strains are highly variable and exhibit extraordinary mutability. Despite condom usage and pre-exposure prophylaxis as excellent prevention strategies, lack of accessibility in some developing countries and low adherence due to sociocultural factors continue to act as barriers in reducing the HIV epidemic. Microbicides are topical therapies developed to prevent HIV and other sexually transmitted infections during intercourse. Microbicides applied vaginally or rectally are intended to prevent HIV infection at the site of transmission by either inhibiting its entry into immune cells or prevent viral replication. This review will summarize some of the current state-of-the-art microbicide formulations that are in preclinical and clinical stages of development and discuss some of the challenges associated with microbicide development.

Similar articles

See all similar articles

Cited by 1 article

  • Antiretroviral drug-S for a possible HIV elimination.
    Agas A, Schuetz H, Mishra V, Szlachetka AM, Haorah J. Agas A, et al. Int J Physiol Pathophysiol Pharmacol. 2019 Aug 15;11(4):149-162. eCollection 2019. Int J Physiol Pathophysiol Pharmacol. 2019. PMID: 31523362 Free PMC article.

Publication types

MeSH terms